The Rapid Micro Blog


Our blog will keep you informed of new and noteworthy technologies, reviews of recent publications and presentations, upcoming conferences and training events, and what's changing in the rapid and alternative microbiological methods world.

New Rapid Test to Diagnose Syphilis and Other STIs in Under an Hour 

Image created by Dr. Michael J. Miller

Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first portable point-of-care test that detects four common sexually transmitted infections at once, in under an hour. The test, which detects syphilis, a high-burden infection, could significantly reduce transmission and improve access to timely treatment. 

Many sexually transmitted infections manifest with overlapping symptoms but require vastly different treatments. Early symptoms of syphilis, for example, often causes genital sores that are difficult to distinguish from those caused by herpes simplex virus (HSV).  

Without rapid, multi-pathogen testing, clinicians may rely solely on symptoms or test for a single infection, increasing the risk of misdiagnosis and delayed care.  

A study published in The Lancet Microbe describes the tool in detail: a next-generation CRISPR-based diagnostic that can simultaneously detect and distinguish between  the DNA and RNA of multiple pathogens at the same time. In addition to syphilis, the test identifies the bacterial and viral causes of other sexually transmitted infections including herpes, chlamydia and gonorrhoea, while also detecting a key antibiotic-resistance marker in gonorrhoea at the point of care, a critical advance amid growing global antimicrobial resistance. 

The University of Melbourne’s Matthew O’Neill, Research Support Officer at the Doherty Institute and co-first author of the paper, said the test delivers results in under an hour on a fully portable device, without the need for laboratory infrastructure.  

“When benchmarked against gold-standard laboratory PCR, the rapid test showed 97 –100 per cent accuracy in correctly identifying negative results, a level of precision important for safe, evidence-based treatment decisions,” he added.  

Syphilis is a growing public health threat in Australia, with diagnoses having more than doubled over the past decade, with around 6,000 cases reported in 2024.   

In August 2025, Australia’s Chief Medical Officer declared it a Communicable Disease Incident of National Significance (CDINS) as cases continued to rise.   

When syphilis is mistaken for other infections, delayed treatment allows disease progression and increases the risk of serious but preventable complications, including infertility, miscarriage and congenital syphilis.  

The University of Melbourne’s Dr Shivani Pasricha, Laboratory Head at the Doherty Institute and senior author of the paper, said concurrent research published in the Lancet Primary Care earlier this year, conducted in urban Victoria in collaboration with, and led by researchers from Melbourne Sexual Health Centre, showed that sometimes patients tested for herpes alone were  positive for syphilis, making this tool critical.  

“Syphilis has long been known as the great mimicker. Correct treatment depends on correct diagnosis,” said Dr Pasricha.  

“This novel enables accurate diagnosis and treatment immediately, without waiting days for laboratory testing or requiring multiple clinic visits,” she added.   

The technology can also support broader use of self-collected samples, making testing more accessible and acceptable for patients and accelerating pathways to treatment.  

“This makes it particularly valuable for regional, remote and underserved communities, where diagnostic delays are common and STI rates are often higher.”  

The researchers will now move the device into implementation trials, aiming for routine clinical use within the next five years.  

Reference

Summary

Background

Timely, point-of-care diagnosis of sexually transmitted infections (STIs) is crucial for enabling prompt treatment and reducing transmission. We aimed to develop a portable, multiplexed, CRISPR-based assay panel for the detection of Neisseria gonorrhoeae (including the ciprofloxacin resistance marker gyrA S91F), Chlamydia trachomatisTreponema pallidum, and herpes simplex virus (HSV).

Methods

In this laboratory development and evaluation study, we developed and optimised four multiplexed, CRISPR-based, diagnostic STI assays for point-of-care use. The complete assay panel comprised a CRISPR TP–HSV (cTP–HSV) panel for the detection of T pallidum and pan-HSV, with reflex testing to distinguish HSV-1 from HSV-2, and a CRISPR NG–CT (cNG–CT) panel for the detection of N gonorrhoeae and C trachomatis, with reflex testing to detect N gonorrhoeae using two additional genome regions and to identify the gyrA S91F mutation. Each pathogen was targeted at two independent genomic regions by isothermal amplification and CRISPR-Cas reaction using Cas12a and Cas13a, each with distinct fluorescent reporters. Analytical specificity and limits of detection (LODs) were determined, and a retrospective, masked concordance study was conducted on genomic DNA from 900 clinical samples (400 for cTP–HSV and reflex testing and 500 for cNG–CT and reflex testing), using quantitative PCR as the reference standard. The diagnostic accuracy of the test was assessed by analysis of receiver operating characteristic curves.

Findings

The overall sensitivity of the TP–HSV CRISPR assay was 82·5% (95% CI 74·0–88·7) for T pallidum and 94·4% (90·2–97·0) for pan-HSV; LODs were 6·2 copies per μL for T pallidum and 7·8 copies per μL for HSV. Reflex testing gave sensitivities of 97·0% (91·1–99·3) for HSV-1 and 96·0% (89·7–98·7) for HSV-2. The NG–CT CRISPR assay had an overall sensitivity of 80·0% (74·0–84·9) for N gonorrhoeae and 73·0% (65·5–79·3) for C trachomatis, with a LOD of 3·9 copies per μL for both pathogens. Reflex testing for the detection of the gyrA S91F mutation in N gonorrhoeae showed an overall sensitivity of 63·1% (55·1–70·4); however, this was dependent on sample type, with a sensitivity of 85·7% (46·7–99·5) in genital samples and 61·2% (52·8–68·9) in extragenital samples. For all pathogens, assay sensitivity was positively correlated with pathogen load. Area under the curve (AUC) values were 0·90 for T pallidum and 0·99 for pan-HSV in the TP–HSV assay, with values of 0·99 for HSV-1 and 0·97 for HSV-2 obtained in the reflex HSV-1–HSV-2 assay. For the cNG–CT assay, AUC values were 0·90 for N gonorrhoeae and 0·85 for C trachomatis, with a value of 0·72 obtained for gyrA S91F in the reflex cNG–gyrA assay.

Interpretation

Our multiplexed, CRISPR-based, point-of-care platform achieved performance consistent with WHO target product profiles for N gonorrhoeae and T pallidum. Proof-of-concept detection of the gyrA S91F resistance marker highlights its potential for resistance-guided therapy. Although optimisation is required before large-scale deployment, this suite offers a promising approach for rapid, decentralised, and resistance-informed STI diagnosis, particularly in resource-limited settings.



Post a Comment

Previous Post Next Post

Contact Form